On January 21, 2025 Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, reported that the first two patients have been treated in the company’s Phase I/II clinical trial (Press release, Neogap Therapeutics, JAN 21, 2025, View Source;personalised-immunotherapy-trial,c4093680 [SID1234649794]). The trial investigates the safety and tolerability of a new, tailored treatment for advanced colorectal cancer, a disease with significant medical needs and limited treatment options.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Colorectal cancer affects two million people worldwide annually and is the third most common cancer type. For patients with metastatic disease, survival prospects are limited, underscoring the need for new, effective treatments. Neogap’s immunotherapy, pTTL (personalised Tumour Trained Lymphocytes), is being developed to address these challenges by offering a personalised treatment based on the patient’s own immune cells.
The clinical trial is being conducted in Sweden at Karolinska University Hospital and Danderyd’s Hospital in Stockholm, as well as Västmanland Hospital in Västerås. The trial targets patients with stage IV metastatic colorectal cancer. Patients are being continuously recruited nationwide, and a total of 12–16 patients will receive the treatment. The primary aim is to evaluate safety and tolerability while collecting data on treatment response.
"We are delighted to have treated the first patients – this is a significant milestone in our clinical trial and our mission to develop curative treatments for critically ill cancer patients. We have an outstanding trial team and look forward to the upcoming results," says Samuel Svensson, CEO of Neogap Therapeutics.
About Neogap’s immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. The therapy combines sophisticated DNA sequencing with T-cell expansion to deliver a precision treatment for solid tumours. It is powered by Neogap’s patented technologies, PIOR and EpiTCer. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.
The clinical trial is conducted in collaboration with the following units:
Phase 1 unit, Center for Clinical Cancer Studies, Theme Cancer, Karolinska University Hospital Solna, Stockholm, Sweden
Medical Unit Cell therapy and Allogeneic stem cell transplantation (ME CAST), Theme Cancer, Karolinska University Hospital Huddinge, Stockholm, Sweden
Medical Unit Pelvic cancer – Colorectal cancer, Theme Cancer, Karolinska University Hospital Solna, Stockholm, Sweden
Department of Surgery, Västmanlands Hospital, Västerås, Sweden
Department of Surgery and Urology, Danderyd’s Hospital, Stockholm, Sweden